Author name: Leonardo Arias

By combining surgical video with other insights, Jegatheeswaran hopes Johnson & Johnson can support better outcomes in procedures.

The nonprofit said it’s feeling growing pressure from higher utilization in its health plan and heightened care delivery costs. It’s also preparing to face fallout from policy changes in Washington.

CBER Chief Vinay Prasad reclaimed his job less than two weeks after his mysterious exit; MAHA implementor Gray Delany is out after reportedly sparring with other agency officials over communications strategy; Eli Lilly’s first Phase III readout for oral obesity drug orforglipron missed analyst expectations; and Arrowhead Pharmaceuticals addresses the recent woes of its of

Contratar un servicio de ayuda a domicilio para un familiar mayor o en situación de dependencia es una decisión importante. Implica aspectos económicos, emocionales y organizativos, por lo que hacerlo bien puede marcar la diferencia en la calidad de vida de la persona atendi …

The layoffs will not spare Generation’s R&D team, which will initially be retained while the biotech completes its strategic review but will eventually be let go.

The CMS plans to trial prior authorization requirements in traditional Medicare. A group of Democrat representatives think that’s a bad idea based on the tool’s track record in Medicare Advantage.

Jefferies analysts said these detailed safety outcomes confirm the gene therapy’s positive risk/benefit profile in ambulatory patients with Duchenne muscular dystrophy.

Insmed’s Brinsupri is the first DPP1 inhibitor approved by the FDA and the first treatment for bronchiectasis to reach the market.

Texas Attorney General Ken Paxton claims that through an alleged kickback scheme Eli Lilly “fraudulently sought to maximize profits at taxpayer expense.”

President Donald Trump loves a deal, but Most Favored Nation drug pricing isn’t a good one for anyone.